![Andrew John Michael Duley](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Andrew John Michael Duley
Directeur/Bestuurslid bij Dietary Assessment Ltd.
Oorsprong van het eerstegraads netwerk van Andrew John Michael Duley
Entiteit | Type entiteit | Industrie | |
---|---|---|---|
Lunac Therapeutics Ltd.
![]() Lunac Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Lunac Therapeutics Ltd. engages in the identification and development of anticoagulants. The company was founded by Helen Philippou and Richard Foster on April 18, 2018 and is headquartered in Leeds, the United Kingdom.
3
| Holding Company | Pharmaceuticals: Major | 3 |
Dietary Assessment Ltd.
![]() Dietary Assessment Ltd. Packaged SoftwareTechnology Services Dietary Assessment Ltd. provides quick and easy to use nutrition software that allows users to track, monitor, and analyze nutrient intake. The company is based in Leeds, UK. The software was created and validated by academics and is suitable for research, teaching, and healthcare purposes. The British company's myfood24 software has been tailored to support classroom learning and to develop critical skills and capacity in nutrition and health. It can also be used by healthcare professionals to support the prevention, early intervention, and management of diet-related diseases. The company was founded in 2017 by Janet Cade, and the CEO is Stephen Michael Kerridge.
2
| Holding Company | Packaged Software | 2 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Andrew John Michael Duley via zijn persoonlijke netwerk
Onderneming | Sector | Gelieerde personen | Hoofdpost |
---|---|---|---|
Epidarex Capital Partners LLC
![]() Epidarex Capital Partners LLC Investment ManagersFinance Epidarex Capital Partners LLC (Epidarex Capital) is a venture capital firm founded in 2010 by Kyparissia Sirinakisvin. The firm is headquartered in Bethesda, Maryland. | Investment Managers | Private Equity Analyst | |
The University of Edinburgh | College/University | Doctorate Degree | |
Caldan Therapeutics Ltd.
![]() Caldan Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Caldan Therapeutics Ltd. provides novel therapeutics targeting free fatty acid. It focuses on developing drugs in order to deliver anti-diabetic effects in multiple tissues and organs. The company was founded by Graeme Milligan and Trond Ulven and is headquartered in Edinburgh, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
Leucid Bio Ltd.
![]() Leucid Bio Ltd. Miscellaneous Commercial ServicesCommercial Services Leucid Bio Ltd. is a clinical-stage biotechnology company based in London, UK. The British company develops novel, lateral car cell therapies for the treatment of refractory cancers, with a focus on developing next-generation cell therapies for the benefit of individuals with hard-to-treat solid tumors. The company's operations are based at Guys Hospital, enabling them to maintain a patient-centric focus. Leucid's goal is to develop CAR-T therapies with more durable responses, improving treatment outcomes and saving the lives of patients with refractory cancers. Leucid was established to translate 20 years of Kings College research in the CAR-T field and is led by a highly experienced management team, including scientific founder John Maher. Filippo Joseph Petti has been the CEO of the company since 2023. | Miscellaneous Commercial Services | Director/Board Member | |
Curve Therapeutics Ltd.
![]() Curve Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Curve Therapeutics Ltd. operates as a drug-discovery company. It engages on the development of innovative technologies to address undruggable disease-modifying targets, with an in-house focus on cancer. The company was founded in 2019 and is headquartered in London, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
Transine Therapeutics Ltd.
![]() Transine Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Transine Therapeutics Ltd. is an RNA platform company based in Cambridge, UK. The British company is developing a novel class of therapeutic RNAs called SINEUPs, which can upregulate protein expression with a superior level of control and specificity across an unprecedented range of diseases and applications. The company's proprietary technology allows them to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies. The SINEUP platform boosts the expression of almost any chosen target protein by binding precisely to the mRNA that encodes it and enhancing its translation. This technology massively extends the druggable proteome and represents an entirely new mechanism of action, ideally suited to address currently hard-to-treat diseases. The company was founded in 2018 by Stefano Gustincich and Piero Carninci. Jan Thirkettle has been the CEO of the company since 2021. | Pharmaceuticals: Major | Private Equity Investor |
Statistieken
Internationaal
Verenigd Koninkrijk | 7 |
Sectoraal
Commercial Services | 4 |
Finance | 2 |
Consumer Services | 2 |
Health Technology | 2 |
Operationeel
Director/Board Member | 6 |
Founder | 3 |
Private Equity Investor | 2 |
Private Equity Analyst | 1 |
Doctorate Degree | 1 |
Sterkste connecties
Insiders | |
---|---|
Mary Canning | 7 |
Helen Philippou | 1 |
Richard Foster | 1 |
Janet Cade | 1 |
Stephen Michael Kerridge | 1 |
- Beurs
- Insiders
- Andrew John Michael Duley
- Bedrijfsconnecties